- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Maharashtra governor's wake-up call to tackle 'lifestyle diseases'
Mumbai: Maharashtra Governor C.V. Rao on Saturday asked the Indian pharmaceutical industry to develop drugs for lifestyle diseases like diabetes, hypertension, cardiovascular ailments and tuberculosis, among others.
Speaking at the golden jubilee celebrations of the Organisation of Pharmaceutical Producers of India (OPPI) here, the governor said lifestyle diseases were playing havoc in the country.
Rao urged the research-based pharma industry to lay renewed thrust on research and innovation and significantly hike investments in drug development and research activities.
"The senior population in India, which is currently 90 million, would touch around 173 million in the next 10 years and the OPPI must make comprehensive plans for their physical, financial, emotional safety and well-being," Rao said.
He lauded the OPPI for "improving the life quality of Indian and also from other under-developed and developing countries" besides partnering India's growth and development vide technical collaborations, disease awareness programmes, patient-access initiatives and drug safety efforts.
To mark the OPPI milestone, Rao felicitated eminent people like Dr. Tarun Gupta, Dr. J. N. Banerjee, Prof. R.D. Joshi, Ranjit Shahani, Dr. Prathap Reddy, Dr. D. B. Gupta for their outstanding contributions to OPPI.
OPPI is an organisation of research-based pharma companies in the country with members like Abbott, Bayer's, GSK, Merck, Novartis, Pfizer, Sanofi, etc
Speaking at the golden jubilee celebrations of the Organisation of Pharmaceutical Producers of India (OPPI) here, the governor said lifestyle diseases were playing havoc in the country.
Rao urged the research-based pharma industry to lay renewed thrust on research and innovation and significantly hike investments in drug development and research activities.
"The senior population in India, which is currently 90 million, would touch around 173 million in the next 10 years and the OPPI must make comprehensive plans for their physical, financial, emotional safety and well-being," Rao said.
He lauded the OPPI for "improving the life quality of Indian and also from other under-developed and developing countries" besides partnering India's growth and development vide technical collaborations, disease awareness programmes, patient-access initiatives and drug safety efforts.
To mark the OPPI milestone, Rao felicitated eminent people like Dr. Tarun Gupta, Dr. J. N. Banerjee, Prof. R.D. Joshi, Ranjit Shahani, Dr. Prathap Reddy, Dr. D. B. Gupta for their outstanding contributions to OPPI.
OPPI is an organisation of research-based pharma companies in the country with members like Abbott, Bayer's, GSK, Merck, Novartis, Pfizer, Sanofi, etc
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751
Next Story